The purpose of this study is to examine the accuracy of wearable technology to detect and characterize smoking behavior. The study consists of one visit and will last approximately one hour. We are seeking adult (? 18 years old) male and female smokers to participate. Compensation is available for those that qualify.
This study is investigating the effects of combining 2 medications, Varenicline (commonly known as Chantix®) and N-acetylcysteine, on smoking behavior in daily cigarette smokers who are interested in quitting smoking. The study consists of 10 visits over 6 weeks. Compensation is available for those that qualify. Smokers must be between the ages of 18 and 55.
Cigarette smoking is the leading preventable cause of death and disability in the U.S. and individuals with elevated depression symptoms or clinically diagnosed major depressive disorder (MDD) smoke at significantly higher rates than non-depressed individuals. Elevated negative affect and affective dysregulated emotional control may contribute to greater smoking among individuals with MDD. The proposed research will shed new light on the neural mechanisms that govern associations between depression and smoking. Despite known and costly associations between these factors, little is known regarding their co-occurrence and such information will provide a foundation for the development of novel and more effective interventions. We are recruiting adult smokers and nonsmokers, and individuals with or without depression, ages 18 and older to participate.